deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 1-arm NCT03610971

Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors

Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

Sponsor: H. Jean Khoury Cure CML Consortium

Conditions Chronic Myeloid Leukemia, Chronic Phase Chronic Phase Chronic Myeloid Leukemia
Interventions BCR-ABL Tyrosine Kinase Inhibitor (TKI) Ruxolitinib
Updated 40 times since 2018 Last updated: Jan 27, 2026 Started: Nov 19, 2019 Primary completion: Sep 25, 2025 Completion: Oct 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Chronic Myeloid Leukemia, Chronic Phase and Chronic Phase Chronic Myeloid Leukemia and is currently ongoing. H. Jean Khoury Cure CML Consortium leads this study, which shows 40 recorded versions since 2019 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Aug 2018 – ~Dec 2018 · 4 months · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Jun 2019 · 5 months · monthly snapshot~Jun 2019 – ~Sep 2019 · 3 months · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Feb 2020 · 2 months · monthly snapshot~Feb 2020 – ~Apr 2020 · 2 months · monthly snapshot~Apr 2020 – ~Jun 2020 · 2 months · monthly snapshot~Jun 2020 – ~Sep 2020 · 3 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~May 2021 · 2 months · monthly snapshot~May 2021 – ~Sep 2021 · 4 months · monthly snapshot~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~Feb 2022 · 2 months · monthly snapshot~Feb 2022 – ~Mar 2022 · 28 days · monthly snapshot~Mar 2022 – ~May 2022 · 2 months · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Sep 2022 · 3 months · monthly snapshot~Sep 2022 – ~Feb 2023 · 5 months · monthly snapshot~Feb 2023 – ~Jun 2023 · 4 months · monthly snapshot~Jun 2023 – ~Aug 2023 · 2 months · monthly snapshot~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshot~Sep 2023 – ~Nov 2023 · 2 months · monthly snapshot~Nov 2023 – ~Apr 2024 · 5 months · monthly snapshot~Apr 2024 – ~May 2024 · 30 days · monthly snapshot~May 2024 – ~Jun 2024 · 31 days · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Dec 2024 · 2 months · monthly snapshot~Dec 2024 – ~Mar 2025 · 3 months · monthly snapshot~Mar 2025 – ~Apr 2025 · 31 days · monthly snapshot~Apr 2025 – ~Jun 2025 · 2 months · monthly snapshot~Jun 2025 – ~Nov 2025 · 5 months · monthly snapshot~Nov 2025 – ~Feb 2026 · 3 months · monthly snapshot~Feb 2026 – present · 7 months · monthly snapshot

Change History

40 versions recorded

  1. Feb 2026 — Present [monthly]

    Active Not Recruiting PHASE2

  2. Nov 2025 — Feb 2026 [monthly]

    Active Not Recruiting PHASE2

  3. Jun 2025 — Nov 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Apr 2025 — Jun 2025 [monthly]

    Active Not Recruiting PHASE2

  5. Mar 2025 — Apr 2025 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

▶ Show 35 earlier versions

  1. Dec 2024 — Mar 2025 [monthly]

    Recruiting PHASE2

  2. Oct 2024 — Dec 2024 [monthly]

    Recruiting PHASE2

  3. Sep 2024 — Oct 2024 [monthly]

    Recruiting PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  5. Jun 2024 — Jul 2024 [monthly]

    Recruiting PHASE2

  6. May 2024 — Jun 2024 [monthly]

    Recruiting PHASE2

  7. Apr 2024 — May 2024 [monthly]

    Recruiting PHASE2

  8. Nov 2023 — Apr 2024 [monthly]

    Recruiting PHASE2

  9. Sep 2023 — Nov 2023 [monthly]

    Recruiting PHASE2

  10. Aug 2023 — Sep 2023 [monthly]

    Recruiting PHASE2

  11. Jun 2023 — Aug 2023 [monthly]

    Recruiting PHASE2

  12. Feb 2023 — Jun 2023 [monthly]

    Recruiting PHASE2

  13. Sep 2022 — Feb 2023 [monthly]

    Recruiting PHASE2

  14. Jun 2022 — Sep 2022 [monthly]

    Recruiting PHASE2

  15. May 2022 — Jun 2022 [monthly]

    Recruiting PHASE2

  16. Mar 2022 — May 2022 [monthly]

    Recruiting PHASE2

  17. Feb 2022 — Mar 2022 [monthly]

    Recruiting PHASE2

  18. Dec 2021 — Feb 2022 [monthly]

    Recruiting PHASE2

  19. Sep 2021 — Dec 2021 [monthly]

    Recruiting PHASE2

  20. May 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  21. Mar 2021 — May 2021 [monthly]

    Recruiting PHASE2

  22. Feb 2021 — Mar 2021 [monthly]

    Recruiting PHASE2

  23. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE2

  24. Sep 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

    Status: Active Not Recruiting → Recruiting

  25. Jun 2020 — Sep 2020 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  26. Apr 2020 — Jun 2020 [monthly]

    Recruiting PHASE2

  27. Feb 2020 — Apr 2020 [monthly]

    Recruiting PHASE2

  28. Dec 2019 — Feb 2020 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  29. Nov 2019 — Dec 2019 [monthly]

    Not Yet Recruiting PHASE2

  30. Oct 2019 — Nov 2019 [monthly]

    Not Yet Recruiting PHASE2

  31. Sep 2019 — Oct 2019 [monthly]

    Not Yet Recruiting PHASE2

  32. Jun 2019 — Sep 2019 [monthly]

    Not Yet Recruiting PHASE2

  33. Jan 2019 — Jun 2019 [monthly]

    Not Yet Recruiting PHASE2

  34. Dec 2018 — Jan 2019 [monthly]

    Not Yet Recruiting PHASE2

  35. Aug 2018 — Dec 2018 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • H. Jean Khoury Cure CML Consortium
  • H. Lee Moffitt Cancer Center and Research Institute
  • Incyte Corporation
Data source: H. Lee Moffitt Cancer Center and Research Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations